Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats

Diabetes, Obesity and Metabolism

Volumn 17, Issue 7, 2015, Pages 703-707

  Lundh, M ^a,b   Galbo, T ^c   Poulsen, S S ^b   Mandrup Poulsen, T ^b,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antidiabetic drug; Beta cell; Endocrine therapy; Insulin secretion; Type 2 diabetes; Zucker diabetic fatty rat

Indexed keywords

BRD 3308; C PEPTIDE; GLUCOSE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; INSULIN; UNCLASSIFIED DRUG; FATTY ACID; GLUCOSE BLOOD LEVEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL PROTECTION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG TOLERABILITY; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; GLUCOTOXICITY; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; LIPOTOXICITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; RAT; STEADY STATE; WEIGHT GAIN; ZUCKER DIABETIC FATTY RAT; ANIMAL; BLOOD; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; INSULIN RESISTANCE; METABOLISM; SECRETION (PROCESS); ZUCKER RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; GLUCOSE CLAMP TECHNIQUE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; OBESITY; RATS; RATS, ZUCKER; WEIGHT GAIN;

EID: 84931957970     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12470     Document Type: Article

References (11)

1. Halban PA, Polonsky KS, Bowden DW etal. Beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. J Clin Endocrinol Metab 2014; 99: 1983-1992.
2. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014; 124: 30-39.
3. Dinarello CA, Fossati G, Mascagni P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med 2011; 17: 333-352.
4. Christensen DP, Dahllof M, Lundh M etal. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol Med 2011; 17: 378-390.
5. Lundh M, Christensen DP, Rasmussen DN etal. Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines. Diabetologia 2010; 53: 2569-2578.
6. Pick A, Clark J, Kubstrup C etal. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998; 47: 358-364.
7. Plaisance V, Rolland L, Gmyr V etal. The class I histone deacetylase inhibitor MS-275 prevents pancreatic beta cell death induced by palmitate. J Diabetes Res 2014; Epub 2014 Dec 31.
8. Galmozzi A, Mitro N, Ferrari A etal. Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. Diabetes 2013; 62: 732-742.
9. Chou DH, Holson EB, Wagner FF etal. Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis. Chem Biol 2012; 19: 669-673.
10. Lundh M, Christensen DP, Damgaard NM etal. Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children. Diabetologia 2012; 55: 2421-2431.
11. You SH, Lim HW, Sun Z, Broache M, Won KJ, Lazar MA. Nuclear receptor co-repressors are required for the histone-deacetylase activity of HDAC3 in vivo. Nat Struct Mol Biol 2013; 20: 182-187.